FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339103600> ?p ?o ?g. }

• W2339103600 endingPage "32209" @default.
• W2339103600 startingPage "32200" @default.
• W2339103600 abstract "// David T. Coleman 1, * , Alana L. Gray 1, * , Charles A. Stephens 1, * , Matthew L. Scott 1 , James A. Cardelli 1 1 Louisiana State University Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, LA, USA * These authors contributed equally to this work Correspondence to: David T. Coleman, email: dcole1@lsuhsc.edu Keywords: cancer-associated fibroblast, cardiac glycosides, tumor microenvironment, drug screen, digoxin Received: January 29, 2016      Accepted: March 14, 2016      Published: April 06, 2016 ABSTRACT The tumor microenvironment, primarily composed of myofibroblasts, directly influences the progression of solid tumors. Through secretion of growth factors, extracellular matrix deposition, and contractile mechanotransduction, myofibroblasts, or cancer-associated fibroblasts (CAFs), support angiogenesis and cancer cell invasion and metastasis. The differentiation of fibroblasts to CAFs is primarily induced by TGF-β from cancer cells. To discover agents capable of blocking CAF differentiation, we developed a high content immunofluorescence-based assay to screen repurposed chemical libraries utilizing fibronectin expression as an initial CAF marker. Screening of the Prestwick chemical library and NIH Clinical Collection repurposed drug library, totaling over 1700 compounds, identified cardiac glycosides as particularly potent CAF blocking agents. Cardiac glycosides are traditionally used to regulate intracellular calcium by inhibiting the Na + /K + ATPase to control cardiac contractility. Herein, we report that multiple cardiac glycoside compounds, including digoxin, are able to inhibit TGF-β-induced fibronectin expression at low nanomolar concentrations without undesirable cell toxicity. We found this inhibition to hold true for multiple fibroblast cell lines. Using real-time qPCR, we determined that digoxin prevented induction of multiple CAF markers. Furthermore, we report that digoxin is able to prevent TGF-β-induced fibroblast contraction of extracellular matrix, a major phenotypic consequence of CAF differentiation. Assessing the mechanism of inhibition, we found digoxin reduced SMAD promoter activity downstream of TGF-β, and we provide data that the effect is through inhibition of its known target, the Na + /K + ATPase. These findings support a critical role for calcium signaling during CAF differentiation and highlight a novel, repurposable modality for cancer therapy." @default.
• W2339103600 created "2016-06-24" @default.
• W2339103600 creator A5028190426 @default.
• W2339103600 creator A5028983844 @default.
• W2339103600 creator A5040638303 @default.
• W2339103600 creator A5060374488 @default.
• W2339103600 creator A5077826580 @default.
• W2339103600 date "2016-04-06" @default.
• W2339103600 modified "2023-10-18" @default.
• W2339103600 title "Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation" @default.
• W2339103600 cites W1513192269 @default.
• W2339103600 cites W1837965070 @default.
• W2339103600 cites W1868626511 @default.
• W2339103600 cites W1914659192 @default.
• W2339103600 cites W1962115721 @default.
• W2339103600 cites W1969474715 @default.
• W2339103600 cites W1975433241 @default.
• W2339103600 cites W1993771588 @default.
• W2339103600 cites W1995555978 @default.
• W2339103600 cites W2008204899 @default.
• W2339103600 cites W2011272270 @default.
• W2339103600 cites W2015270653 @default.
• W2339103600 cites W2023974524 @default.
• W2339103600 cites W2025199554 @default.
• W2339103600 cites W2029910234 @default.
• W2339103600 cites W2032283922 @default.
• W2339103600 cites W2033998652 @default.
• W2339103600 cites W2037038224 @default.
• W2339103600 cites W2047141937 @default.
• W2339103600 cites W2052786158 @default.
• W2339103600 cites W2062809449 @default.
• W2339103600 cites W2072703892 @default.
• W2339103600 cites W2074378720 @default.
• W2339103600 cites W2077895663 @default.
• W2339103600 cites W2088097413 @default.
• W2339103600 cites W2088110734 @default.
• W2339103600 cites W2091277841 @default.
• W2339103600 cites W2096262488 @default.
• W2339103600 cites W2096764577 @default.
• W2339103600 cites W2099055911 @default.
• W2339103600 cites W2099703259 @default.
• W2339103600 cites W2101037339 @default.
• W2339103600 cites W2101728107 @default.
• W2339103600 cites W2102251969 @default.
• W2339103600 cites W2111378771 @default.
• W2339103600 cites W2112740677 @default.
• W2339103600 cites W2116746706 @default.
• W2339103600 cites W2117733417 @default.
• W2339103600 cites W2122146830 @default.
• W2339103600 cites W2127979123 @default.
• W2339103600 cites W2129564497 @default.
• W2339103600 cites W2132931673 @default.
• W2339103600 cites W2143841173 @default.
• W2339103600 cites W2144316016 @default.
• W2339103600 cites W2146303187 @default.
• W2339103600 cites W2157824210 @default.
• W2339103600 cites W2158303916 @default.
• W2339103600 cites W2160698607 @default.
• W2339103600 cites W2162647235 @default.
• W2339103600 cites W2173889361 @default.
• W2339103600 cites W2262649717 @default.
• W2339103600 cites W2300962485 @default.
• W2339103600 cites W2400311414 @default.
• W2339103600 cites W2417590172 @default.
• W2339103600 cites W287920933 @default.
• W2339103600 cites W332390835 @default.
• W2339103600 doi "https://doi.org/10.18632/oncotarget.8609" @default.
• W2339103600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5078007" @default.
• W2339103600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27058757" @default.
• W2339103600 hasPublicationYear "2016" @default.
• W2339103600 type Work @default.
• W2339103600 sameAs 2339103600 @default.
• W2339103600 citedByCount "19" @default.
• W2339103600 countsByYear W23391036002016 @default.
• W2339103600 countsByYear W23391036002017 @default.
• W2339103600 countsByYear W23391036002018 @default.
• W2339103600 countsByYear W23391036002019 @default.
• W2339103600 countsByYear W23391036002020 @default.
• W2339103600 countsByYear W23391036002021 @default.
• W2339103600 countsByYear W23391036002022 @default.
• W2339103600 crossrefType "journal-article" @default.
• W2339103600 hasAuthorship W2339103600A5028190426 @default.
• W2339103600 hasAuthorship W2339103600A5028983844 @default.
• W2339103600 hasAuthorship W2339103600A5040638303 @default.
• W2339103600 hasAuthorship W2339103600A5060374488 @default.
• W2339103600 hasAuthorship W2339103600A5077826580 @default.
• W2339103600 hasBestOaLocation W23391036001 @default.
• W2339103600 hasConcept C121608353 @default.
• W2339103600 hasConcept C126322002 @default.
• W2339103600 hasConcept C142724271 @default.
• W2339103600 hasConcept C185592680 @default.
• W2339103600 hasConcept C189165786 @default.
• W2339103600 hasConcept C207865475 @default.
• W2339103600 hasConcept C2776107976 @default.
• W2339103600 hasConcept C2779013556 @default.
• W2339103600 hasConcept C2780559512 @default.
• W2339103600 hasConcept C502942594 @default.
• W2339103600 hasConcept C55493867 @default.

• next